New research sheds light on gene destruction linked to aggressive prostate cancer

Key points
- Researchers at Queen’s University have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.
- “This discovery gives us a greater understanding of how aggressive prostate cancer develops because we now have some insight into the mechanism by which the PTEN gene is destroyed,” says Jeremy Squire, a professor in the Department of Pathology and Molecular Medicine.
- PTEN is one of a small class of tumor suppressor genes that closely regulates the growth of cells.
- Squire, with his postdoctoral fellow Maisa Yoshimoto, examined cancerous tissue samples and determined that the loss of the PTEN gene occurred close to a large, unstable segment of DNA.
Researchers at Queen’s University have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.
“This discovery gives us a greater understanding of how aggressive prostate cancer develops because we now have some insight into the mechanism by which the PTEN gene is destroyed,” says Jeremy Squire, a professor in the Department of Pathology and Molecular Medicine.
PTEN is one of a small class of tumor suppressor genes that closely regulates the growth of cells. When PTEN is altered or deleted in prostate cells, they lose the ability to make a protein that controls normal growth. Cells can then grow uncontrolled and can develop into a prostate cancer.
Dr. Squire, with his postdoctoral fellow Maisa Yoshimoto, examined cancerous tissue samples and determined that the loss of the PTEN gene occurred close to a large, unstable segment of DNA. Their discovery suggests that proximity of PTEN to this region makes cancer-suppressing genes more prone to being deleted or inactivated.
Researchers discovered the gene using a novel gene-detection technology developed by Dr. Squire and his laboratory. They identified and analyzed with unprecedented accuracy the loss of critical tumour genes using a highly sensitive fluorescent labelling system. The technology significantly improves on current methods for identifying PTEN loss and has the potential to lead to better treatment of prostate cancer patients.
The Del-TECT gene-detection technology was licensed to CymoGen Dx through PARTEQ Innovations, Queen’s technology transfer office last year. CymoGen DX invented the labeling system.
The researchers’ findings appear in the current edition of the journal Genes, Chromosomes and Cancer.
###
Queen's University
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsResearchers Find Ovarian Cancer Risk Related To Inherited Inflammation Genes
In a study conducted by researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the Unites States and the United Kingdom, genes that are known to be involved in inflammation were found to be…
9 February 2012
NewsU-M researchers find genetic rearrangements driving 5 to 7 percent of breast cancers
Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers. These types of genetic recombinations…
21 November 2011
NewsResearchers discover genes involved in colorectal cancer
A jumping gene with the fairy tale name "Sleeping Beauty" has helped to unlock vital clues for researchers investigating the genetics of colorectal cancer. A study published today used the Sleeping Beauty transposon…






